• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Book chapters
    • View Item
    • Home
    • Griffith Research Online
    • Book chapters
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Peptide-Protein Conjugation and Characterization to Develop Vaccines for Group A Streptococcus

    Author(s)
    Eskandari, Sharareh
    Good, Michael F
    Pandey, Manisha
    Griffith University Author(s)
    Good, Michael F.
    Pandey, Manisha
    Eskandari, Sherry
    Year published
    2021
    Metadata
    Show full item record
    Abstract
    Peptide conjugates have been widely used for developing vaccines that prevent common bacterial infections for which peptides alone are either ineffective or provide only short-term protection. Among several carrier proteins, diphtheria toxoid and CRM197 (a genetically detoxified diphtheria toxin) are considered safe and have been used in several licensed vaccines. For developing a vaccine against group A streptococcus (GAS), antigens from conserved region of M protein and the IL-8 protease, SpyCEP, have been identified. In this chapter, we describe a method for producing peptide-conjugate subunit GAS vaccines, which involves ...
    View more >
    Peptide conjugates have been widely used for developing vaccines that prevent common bacterial infections for which peptides alone are either ineffective or provide only short-term protection. Among several carrier proteins, diphtheria toxoid and CRM197 (a genetically detoxified diphtheria toxin) are considered safe and have been used in several licensed vaccines. For developing a vaccine against group A streptococcus (GAS), antigens from conserved region of M protein and the IL-8 protease, SpyCEP, have been identified. In this chapter, we describe a method for producing peptide-conjugate subunit GAS vaccines, which involves maleimide conjugation of peptides to a carrier protein and their subsequent characterization.
    View less >
    Book Title
    Peptide Conjugation
    Volume
    2355
    DOI
    https://doi.org/10.1007/978-1-0716-1617-8_3
    Subject
    Chemical sciences
    Biochemistry and cell biology
    Other chemical sciences
    CRM197
    Conjugate
    Diphtheria toxoid
    GAS
    Group A streptococcus
    Publication URI
    http://hdl.handle.net/10072/407615
    Collection
    • Book chapters

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander